A research report highlights that Yidu Tech (02158) is a leading domestic medical AI company. Its core algorithm, YiduCore, is built on real-world medical data and has been deployed in several top-tier domestic hospitals. Leveraging YiduCore, the company has established three major business segments targeting hospitals, pharmaceutical companies, and patients, with rapid order growth in the first half of fiscal year 2026. Yidu Tech is anticipated to achieve its first annual profit in FY26, while its frequent and substantial share repurchases in 2026 underscore management's confidence.

Core AI Capabilities and Platform

Yidu Tech's AI capabilities have formed a complete closed loop from data to algorithms, application scenarios, and commercialization. YiduCore serves as the central algorithmic engine and the "medical brain" of the company's AI system. It processes over 7 billion authorized real-world medical data records, granting it a disease understanding far superior to general models trained on public datasets. The company has built a platform-level intelligent foundation through its AI middleware, employing a "1+N+X" Copilot product matrix. This structure features one unified AI middleware base, integrating N large language models to empower X business scenarios.

The application of Yidu Tech's AI technology is progressing steadily. In March 2026, the company officially launched Yidu Zhixun, a clinical evidence-based intelligent agent for doctors, now deployed in 50 top hospitals nationwide. In clinical practice, at Sun Yat-sen University Cancer Center, the company's large model improved the accuracy of T-stage analysis in TNM staging from 58% to 90%, reaching the diagnostic level of a chief physician. Additionally, AI has enhanced patient recruitment efficiency by 3-5 times and reduced screening costs by 88%.

AI-Powered Business Segments

Yidu Tech's three business segments revolve around the "hospital-pharmaceutical-insurance-patient" ecosystem, comprising the Big Data Platform and Solutions (AI for Medical), Life Science Solutions (AI for Life Science), and the Health Management Platform and Solutions (AI for Care). AI for Medical serves hospitals and regulators, empowering clinical diagnosis, research, and hospital management. The collaboration with Sun Yat-sen University Cancer Center is a model of AI-enabled healthcare in China. AI for Life Science serves pharmaceutical companies, covering the entire drug lifecycle from clinical trials to real-world studies and commercialization. As of the first half of FY26, it had served 17 of the top 20 multinational pharmaceutical firms. AI for Care targets consumers and governments, operating inclusive insurance products and digital therapeutics. All three segments share the underlying YiduCore intelligent engine, where high-quality clinical data from hospitals enhances drug R&D and real-world studies for pharmaceutical clients, while also empowering risk prediction and health management for insurers. By September 2025, new orders for the AI for Medical segment grew 19.7% year-on-year, with backlog exceeding CNY 400 million. New orders for the AI for Science segment surged 61.1% year-on-year, with a backlog nearing CNY 400 million.

Diversified AI Expansion Strategy

On June 1, 2026, Yidu Tech announced its intention to acquire 100% equity of an online doctor platform for approximately CNY 400 million. By March 2026, this platform had accumulated about 3.5 million registered practicing doctors. Yidu Tech plans to leverage its leading AI capabilities, combined with the acquired company's extensive doctor network and mature medical service channels, to drive the large-scale deployment of AI technology and products. The Southeast Asian market is spearheading the company's overseas expansion. Current overseas revenue primarily comes from Brunei, where it built the BruHealth national health platform covering 90% of the population. Revenue from this segment accounted for 13% of total revenue in the first half of FY26. Beyond Southeast Asia, the company is also exploring international markets like the US and the Middle East.

Profit Growth and Shareholder Returns

Yidu Tech issued a positive profit alert on April 20, 2026, forecasting net profit attributable to shareholders for the fiscal year ending March 31, 2026, to be between CNY 41 million and 56 million. This marks the company's first annual profit since listing, driven primarily by order-driven revenue growth and continuous improvements in profit margins and expense ratios. Concurrently, the company's share repurchase activity has shown an increasing trend in both scale and frequency. Notably, repurchases in February and March 2026 amounted to CNY 58 million and HKD 146 million, respectively, accounting for 82.4% of the total repurchase amount for FY26. These frequent and substantial buybacks demonstrate management's confidence in the company's intrinsic value.